Macular degeneration drug approved

Share this article:

The Food and Drug Administration recently approved a drug for the treatment of the wet form of age-related macular degeneration. The medication is called Eylea. The medication is manufactured by Regeneron Pharmaceuticals. At $1,850 per injection, it costs $1000 less than Genentech's Lucentis. Macular degeneration is the leading cause of severe vision loss among residents in senior living settings.


Share this article:
close

Next Article in Products

More in Products

Bertlesmann buys Relias Learning

Bertelsmann, a media company based in Germany, said last week it is buying Relias Learning from its current owners, Vista Equity Partners and LLR Partners.

Acuity Brands introduces LED collection

Acuity Brands introduces LED collection

Acuity Brands says its new CanoeTM LED Pendant and Sconce Collection from Winona Lighting® can meet the needs of designers in unique spaces.

SwimEx debuts Triton Pool

SwimEx debuts Triton Pool

SwimEx Inc. has announced the Triton, the newest member of its line of fitness and therapy pools. It is available for the commercial and residential markets.